Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Payables (2020 - 2023)

Candel Therapeutics' Payables history spans 4 years, with the latest figure at $250000.0 for Q3 2023.

  • For Q3 2023, Payables fell 74.23% year-over-year to $250000.0; the TTM value through Sep 2023 reached $250000.0, down 74.23%, while the annual FY2022 figure was $380000.0, 76.1% down from the prior year.
  • Payables for Q3 2023 was $250000.0 at Candel Therapeutics, down from $480000.0 in the prior quarter.
  • Across five years, Payables topped out at $1.6 million in Q4 2021 and bottomed at $250000.0 in Q3 2023.
  • The 4-year median for Payables is $921000.0 (2020), against an average of $894272.7.
  • The largest YoY upside for Payables was 108.7% in 2022 against a maximum downside of 76.1% in 2022.
  • A 4-year view of Payables shows it stood at $921000.0 in 2020, then skyrocketed by 72.64% to $1.6 million in 2021, then tumbled by 76.1% to $380000.0 in 2022, then plummeted by 34.21% to $250000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Payables are $250000.0 (Q3 2023), $480000.0 (Q2 2023), and $592000.0 (Q1 2023).